Postrock Partners LLC Invests $380,000 in Edwards Lifesciences Co. (NYSE:EW)

Postrock Partners LLC acquired a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 5,128 shares of the medical research company's stock, valued at approximately $380,000.

A number of other institutional investors also recently modified their holdings of EW. Versor Investments LP boosted its stake in shares of Edwards Lifesciences by 102.5% in the 3rd quarter. Versor Investments LP now owns 4,455 shares of the medical research company's stock valued at $294,000 after purchasing an additional 2,255 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $481,000. MQS Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $245,000. Oppenheimer & Co. Inc. boosted its stake in shares of Edwards Lifesciences by 3.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 38,186 shares of the medical research company's stock valued at $2,520,000 after purchasing an additional 1,441 shares during the last quarter. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund lifted its position in shares of Edwards Lifesciences by 422.3% during the 3rd quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 450,233 shares of the medical research company's stock valued at $29,711,000 after acquiring an additional 364,030 shares during the period. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EW. Piper Sandler boosted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Truist Financial reiterated a "hold" rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Hold" and an average target price of $79.95.

Remove Ads

Edwards Lifesciences Stock Down 0.5 %

Shares of EW stock traded down $0.33 on Tuesday, hitting $70.31. The stock had a trading volume of 3,702,921 shares, compared to its average volume of 4,582,058. The business has a 50 day moving average of $71.68 and a 200 day moving average of $70.34. The stock has a market cap of $41.33 billion, a price-to-earnings ratio of 10.09, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company's stock, valued at $3,189,770.56. The trade was a 16.83 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.